96 related articles for article (PubMed ID: 9300746)
1. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.
Le QT; Fu KK; Kroll S; Ryu JK; Quivey JM; Meyler TS; Krieg RM; Phillips TL
Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):115-26. PubMed ID: 9300746
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in elderly patients with T1 glottic cancer treated with radiotherapy.
Mucha-Małecka A; Małecki K; Amrogowicz N; Biesaga B; Modrzejewski M
Sci Rep; 2021 Sep; 11(1):17717. PubMed ID: 34489495
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation.
Mohamed ASR; Smith BD; Smith JB; Sevak P; Malek JS; Kanwar A; Browne T; Gunn GB; Garden AS; Frank SJ; Morrison WH; Phan J; Zafereo M; Skinner H; Lai SY; Hutcheson KA; Lewin JS; Hessel AE; Thekdi AA; Weber RS; Fuller CD; Rosenthal DI
Laryngoscope; 2020 Jan; 130(1):146-153. PubMed ID: 30756394
[TBL] [Abstract][Full Text] [Related]
4. Carotid dosimetry for T1 glottic cancer radiotherapy.
Garcez K; Lim CC; Whitehurst P; Thomson D; Ho KF; Lowe M; Sykes A; Lee LW; Yap B; Slevin N
Br J Radiol; 2014 Jun; 87(1038):20130754. PubMed ID: 24628251
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of hypofractionation for early-stage glottic carcinoma.
Uysal B; Gamsiz H; Colak O; Beyzadeoglu M
J Cancer Res Ther; 2023 Oct; 19(7):1962-1966. PubMed ID: 38376304
[TBL] [Abstract][Full Text] [Related]
6. A multicenter survey of stage T1 glottic cancer treated with radiotherapy delivered in 2.25-Gy fractions in clinical practice: An initial 5-year analysis.
Itoh Y; Kubota S; Kawamura M; Nomoto Y; Murao T; Yamakawa K; Ishihara S; Hirasawa N; Asano A; Yanagawa S; Naganawa S
Nagoya J Med Sci; 2016 Dec; 78(4):399-406. PubMed ID: 28008195
[TBL] [Abstract][Full Text] [Related]
7. The outcome of early-stage glottic carcinoma patients treated with radiotherapy: Egyptian National Cancer Institute (NCI-Egypt) experience.
Mohamed AE; Hassouna AH; Mosalum HS; Alnagmy AK; Ashour MG
Rep Pract Oncol Radiother; 2023; 28(4):496-505. PubMed ID: 37795222
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Radiotherapy for Stage 1 Glottic Carcinoma: Comparing Accelerated Hyperfractionation and Once-daily Fractionation.
Endo M; Fukuda Y; Okada K; Ogawa K; Nakamura M; Takahashi S; Murakami E; Shibayama C; Kawahara M; Akahane K; Onaga R; Nagatomo T; Kanazawa T; Nishino H; Mori H; Shirai K
In Vivo; 2023; 37(5):2320-2326. PubMed ID: 37652523
[TBL] [Abstract][Full Text] [Related]
9. Effect of Radiological Tumor Thickness on Prognosis of Early Glottic-Squamous Cell Carcinoma Treated With Radiation.
Dagan O; Perlow A; Shoffel-Havakuk H; Biadsee A; Moore A; Ritter A; Gilat H; Popovtzer A; Alkan U
J Voice; 2024 Apr; ():. PubMed ID: 38570226
[TBL] [Abstract][Full Text] [Related]
10. Short treatment time and excellent treatment outcome in accelerated hyperfractionated radiotherapy for T1 glottic cancer.
Tamaki Y; Hieda Y; Yoshida R; Yoshizako T; Fuchiwaki T; Aoi N; Sekihara K; Kitajima K; Kawauchi H; Kitagaki H; Sasaki R; Inomata T
Nagoya J Med Sci; 2015 Nov; 77(4):585-94. PubMed ID: 26663937
[TBL] [Abstract][Full Text] [Related]
11. Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology.
Wilkins A; Melcher A; Somaiah N
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):605-608. PubMed ID: 30041845
[No Abstract] [Full Text] [Related]
12. Protein expression analysis for predicting recurrent laryngeal squamous cell carcinoma.
Thanasan S; Ruangritchankul K; Kitkumthorn N; Keelawat S; Mahattanasakul P
Biomed Rep; 2024 Jan; 20(1):15. PubMed ID: 38124771
[TBL] [Abstract][Full Text] [Related]
13. Daily fraction dose-adjusted radiotherapy policy to avoid prolonging the overall treatment time for early glottic squamous cell carcinoma: a single-institutional retrospective study.
Dekura Y; Yasuda K; Minatogawa H; Uchinami Y; Tsushima N; Suzuki T; Kano S; Mori T; Nishioka K; Kobashi K; Katoh N; Homma A; Aoyama H
J Radiat Res; 2024 Jan; 65(1):63-70. PubMed ID: 37952082
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Role of Stereotactic Body Radiation Therapy for Head and Neck Cancer: Where Do We Stand?
Mohamad I; Karam I; El-Sehemy A; Abu-Gheida I; Al-Ibraheem A; Al-Assaf H; Aldehaim M; Alghamdi M; Alotain I; Ashour M; Bushehri A; ElHaddad M; Hosni A
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894377
[TBL] [Abstract][Full Text] [Related]
15. Real-Time Tracking of Laryngeal Motion via the Surface Depth-Sensing Technique for Radiotherapy in Laryngeal Cancer Patients.
Lee WJ; Leu YS; Chen JS; Dai KY; Hou TC; Chang CT; Li CJ; Hua KL; Chen YJ
Bioengineering (Basel); 2023 Jul; 10(8):. PubMed ID: 37627793
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of hypofractionated versus conventional fractionated radiotherapy for the treatment of men with early glottic cancer: a study in the Brazilian public and private health system.
Lourenção M; Arruda GV; Rocha LP; Galendi JSC; de Oliveira JC; Jacinto AA
BMC Health Serv Res; 2023 Jun; 23(1):592. PubMed ID: 37291564
[TBL] [Abstract][Full Text] [Related]
17. Three-week hypofractionated radiotherapy in early glottic cancer-a single institution retrospective study.
Sudha AS; Kumar RR; Anjanappa M; Kainickal CT; Mathew A; Kunnambath R
Ecancermedicalscience; 2022; 16():1381. PubMed ID: 35919227
[TBL] [Abstract][Full Text] [Related]
18. Laryngectomy-free survival after salvage partial laryngectomy: a systematic review and meta-analysis.
Shapira U; Warshavsky A; Muhanna N; Oestreicher-Kedem Y; Nachalon Y; Ungar OJ; Safadi A; Carmel Neiderman NN; Horowitz G
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):3021-3027. PubMed ID: 35039895
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the maximum standardized uptake value for the locoregional control in early glottic cancer.
Kim D; Ki Y; Joo J; Jeon H; Park D; Nam J; Kim W
Radiat Oncol J; 2021 Dec; 39(4):297-303. PubMed ID: 34986551
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
